Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Antiseptic properties of two calix[4]arenes derivatives on the human coronavirus 229E∗

C. Geller, S. Fontanay, M. Mourer, H. Massimba Dibama, J.-B. Regnouf-de-Vains, C. Finance, R.E. Duval∗

GEVSM, SRSMC, UMR 7565, Nancy-University, CNRS, Faculty of Pharmacy, 5 rue Albert Lebrun, BP 80403, 54001 Nancy Cedex, France

ARTICLE INFO

Article history:
Received 25 June 2010
Received in revised form 1 September 2010
Accepted 14 September 2010

Keywords:
HCoV 229E
tetra-para-Sulfonato-calix[4]arene
1,3-Bis(bithiazolyl)-tetra-para-sulfonato-calix[4]arene
Antiseptic
Virucidal

ABSTRACT

Facing the lack in specific antiviral treatment, it is necessary to develop new means of prevention. In the case of the Coronaviridae family is now recognized as including potent human pathogens causing upper and lower respiratory tract infections as well as nosocomial ones. Within the purpose of developing new antiseptics molecules, the antiseptic virucidal activity of two calix[4]arene derivatives, the tetra-para-sulfonato-calix[4]arene (C4S) and the 1,3-bis(bithiazolyl)-tetra-para-sulfonato-calix[4]arene (C4S-BTZ) were evaluated toward the human coronavirus 229E (HCoV 229E). Comparing these results with some obtained previously with chlorhexidine and hexamidine, (i) these two calixarenes did not show any cytotoxicity contrary to chlorhexidine and hexamidine, (ii) C4S showed as did hexamidine, a very weak activity against HCoV 229E, and (iii) the C4S-BTZ showed a stronger activity than chlorhexidine, i.e. 2.7 and 1.4 log10 reduction in viral titer after 5 min of contact with 10−3 mol L−1 solutions of C4S-BTZ and chlorhexidine, respectively. Thus, the C4S-BTZ appeared as a promising virucidal (antiseptic) molecule.

© 2010 Elsevier B.V. All rights reserved.

The lack in specific antiviral treatments is still persisting, considering the large variety of viruses already circulating among human population and the potential emerging ones. The Coronaviridae family illustrates this problem. Indeed, no specific treatment is available to fight coronaviruses infections, while they are known to be responsible for upper and lower tract infections as well as nosocomial ones. Thus, efficient means of prevention, as an adapted antiseptic-disinfection (ATS-D), should be developed to prevent the environmental spread of such infections.

Human coronaviruses (HCoV) were historically known to be responsible for about 20% of common colds and other upper respiratory tract infections (Larson et al., 1980). Before the SARS (severe acute respiratory syndrome) epidemic in 2002–2003, only two HCoV were known, the 229E strain and the OC43 strain. This serious outbreak, due to a newly discovered HCoV, the SARS-CoV (Ksiazek et al., 2003; Peiris et al., 2003), reinforced the interest into the Coronaviridae family. Indeed, coronaviruses were since involved in more serious respiratory diseases, i.e. bronchitis, bronchiolitis or pneumonia, especially in young children and neonates (Gagneur et al., 2002; Gerna et al., 2006), elderly people (Falsey et al., 2002) and immunosuppressed patients (Gerna et al., 2007; Pene et al., 2003). Furthermore, they have been shown to survive for at least several hours under different environmental conditions (Ijaz et al., 1985; Lai et al., 2005; Rabenau et al., 2005a; Sizun et al., 2000). Finally, their adaptive properties and their ability of species barrier crossing, involve a significant possibility of new coronaviruses emergence (Laude et al., 1998; Li et al., 2005; Vigen et al., 2005). Thus, these specificities (i.e. pathogenicity, potential environmental resistance and evolutionary ability) make the Coronaviridae family a pertinent model for studying ATS-D activity.

New antiviral molecules are urgently needed. Within this purpose, some macrocyclic compounds belonging to the calixarene family (de Fátima et al., 2009; Rodik et al., 2009), have already been shown to be interesting as anti-HIV and anti-HSV agents (Coveney and Costello, 2005; Harris, 1995, 2002; Hwang et al., 1994; Kral et al., 2005; Motornaya et al., 2006). In this field, our team described antiviral properties of various derivatives, such as 1,3-bis(bithiazolyl)-tetra-para-sulfonato-calix[4]arene (C4S-BTZ) and tetra-para-sulfonato-calix[4]arene (C4S) (Mourer et al., 2010) (Fig. 1).
The potential ATS-D activities of C[4]S and C[4]S-BTZ were then estimated on the HCoV 229E (ATCC VR 740), cultivated on L-132 cells (ATCC CCL-5).

To evaluate these properties, a protocol described elsewhere (Geller et al., 2009) has been implemented. It responded to the general imperatives of the only European standard existing (NF EN 14476 + A1) to evaluate ATS-D antiviral activity in human medicine (AFNOR, 2007). According to this standard, a product should induce a 4 log₁₀ reduction in viral titers to quality as an ATS-D antiviral activity. For comparison, American standards recommend a reduction of 3 log₁₀ as efficiency criterion (ASTM, 1996, 1997).

The general principle of our protocol is: (i) to incubate viruses with the test product, at room temperature, for a defined contact time, (ii) to neutralize product activity and (iii) to estimate the loss in viral titers. The neutralization process allows: (i) to stop the potential antiviral activity of the product, (ii) to remove its cytotoxicity and (iii) to prevent interference, due to the potential antiviral activity of the product, (ii) to remove its cytotoxicity and (iii) to prevent interference, due to the potential antiviral activity of the product, (ii) to remove its cytotoxicity and (iii) to prevent interference, due to the potential antiviral activity of the product, (ii) to remove its cytotoxicity and (iii) to prevent interference, due to the potential antiviral activity of the product, (ii) to remove its cytotoxicity and (iii) to prevent interference.

The C[4]S was tested at a concentration of 10⁻³ mol L⁻¹ and contact times of 30 min and 60 min. Because of the very weak activity against HCoV 229E, i.e. 0.5 and 0.6 log₁₀ reduction for contact times of 30 min and 60 min, respectively, no further experiments were performed with C[4]S (Fig. 2).

Results obtained with the C[4]S-BTZ were markedly better. Indeed, at a concentration of 10⁻⁴ mol L⁻¹, it induced log₁₀ reductions of 0.3, 0.6, 0.8 and 1.0 after contact times of 5, 15, 30 and 60 min, respectively. At 10⁻⁵ mol L⁻¹, it induced reductions of 2.7, 2.7, 2.4 and 2.8 log₁₀ in viral titers for the same contact times (Fig. 2).

| Contact times | C[4]S | C[4]S-BTZ |
|---------------|-------|-----------|
| 5 min         | ND    | 0.3 ± 0.2 |
| 15 min        | ND    | 0.3 ± 0.2 |
| 30 min        | 0.3 ± 0.2 | 0.3 ± 0.2 |
| 60 min        | 0.3 ± 0.1 | 0.2 ± 0.1 |

AT-S-D antiviral assays were then conducted. Each experiment was performed in triplicate. To validate these tests, controls, mentioned above, were done the same time, and results are shown for both molecules in Table 1.

![Fig. 1. Structures of the tetra-para-sulfonato-calix[4]arene (C[4]S) and the 1,3-bis(2-thiazolyl)-tetra-para-sulfonato-calix[4]arene (C[4]S-BTZ).](image)

The potential ATS-D activities of C[4]S and C[4]S-BTZ were then estimated on the HCoV 229E (ATCC VR 740), cultivated on L-132 cells (ATCC CCL-5).

To evaluate these properties, a protocol described elsewhere (Geller et al., 2009) has been implemented. It responded to the general imperatives of the only European standard existing (NF EN 14476 + A1) to evaluate ATS-D antiviral activity in human medicine (AFNOR, 2007). According to this standard, a product should induce a 4 log₁₀ reduction in viral titers to quality as an ATS-D antiviral activity. For comparison, American standards recommend a reduction of 3 log₁₀ as efficiency criterion (ASTM, 1996, 1997).

The general principle of our protocol is: (i) to incubate viruses with the test product, at room temperature, for a defined contact time, (ii) to neutralize product activity and (iii) to estimate the loss in viral titers. The neutralization process allows: (i) to stop the potential antiviral activity of the product, (ii) to remove its cytotoxicity and (iii) to prevent interference, due to the test itself, in viral infectivity. It was achieved thanks to a gel filtration method, using Sephadex™ G-25 columns, developed and validated previously (Geller et al., 2009). These assays required appropriate controls especially to check the non retention of viruses by Sephadex™ columns, the absence of interference with viral infectivity, the efficiency of neutralization and the absence of cytotoxicity (Supp. data 1). As recommended by the European Standard NF EN 14476 + A1, controls are validated if the difference between viral titers, with and without treatment, is less than 0.5 log₁₀ (AFNOR, 2007).

Molecular masses of C[4]S and C[4]S-BTZ were 1069.80 g mol⁻¹ and 1365.22 g mol⁻¹, respectively. Thus, they were susceptible to be retained by the Sephadex™ G-25 columns. To assess the non cytotoxicity of the filtrates, cytotoxicity assays and spectrophotometric measurements were conducted. Two concentrations for both molecules were tested, i.e. 10⁻⁴ and 10⁻³ mol L⁻¹.

MTT (methy1thiazole tetrazolium) and NR (neutral red) assays were first performed to evaluate cytotoxicity of C[4]S and C[4]S-BTZ on L-132 cells. For both molecules, IC₅₀ (inhibitory concentration 50%) and CC₅₀ (cytotoxic concentration 50%) were higher than 10⁻⁴ mol L⁻¹, even after 168 h, the time required for obtaining the HCoV 229E cytopathogenic effect. The same assays were then performed with the filtrates obtained after filtration of both molecules on Sephadex™ G-25 columns and cytotoxicity was also higher than 10⁻⁴ mol L⁻¹ even after 168 h of incubation.

Spectrophotometric analyses, coupled with regression analyses, allowed to determine the specific parameters of each molecule (Supp. data 2). Retention rates by Sephadex™ G-25 columns were then estimated after evaluation of residual concentration in the filtrates. Retention rates of C[4]S solutions by Sephadex™ G-25 columns were 98.9% and 88.5% for solutions at 10⁻³ mol L⁻¹ and 10⁻⁴ mol L⁻¹, respectively. The lower retention rate of 10⁻⁴ mol L⁻¹ solution was due to calculation limitations. Retention rate of the solution at 10⁻³ mol L⁻¹ was considered as significant. In the case of C[4]S-BTZ, retention rates were 94.8% and 99.4% for solutions of 10⁻³ and 10⁻⁴ mol L⁻¹, respectively (Supp. data 2).

Results obtained with the C[4]S-BTZ were markedly better. Indeed, at a concentration of 10⁻⁴ mol L⁻¹, it induced log₁₀ reductions of 0.3, 0.6, 0.8 and 1.0 after contact times of 5, 15, 30 and 60 min, respectively. At 10⁻⁵ mol L⁻¹, it induced reductions of 2.7, 2.7, 2.4 and 2.8 log₁₀ in viral titers for the same contact times (Fig. 2).

![Table 1](image)

| Contact times | C[4]S⁻¹ | C[4]S-BTZ⁻¹ |
|---------------|---------|------------|
| 5 min         | ND      | 0.3 ± 0.2  |
| 15 min        | ND      | 0.3 ± 0.2  |
| 30 min        | 0.3 ± 0.2 | 0.3 ± 0.2  |
| 60 min        | 0.3 ± 0.1 | 0.2 ± 0.1  |

Non retention of virus after filtration on Sephadex™ G-25 columns

Non retention of virus after filtration on Sephadex™ G-25 columns has been checked out for each tested contact times and neutralization efficiency for each tested concentrations. To be accepted, a control should present a log₁₀ difference lower than 0.5 log₁₀.

* Expressed as log₁₀ reduction.
* Not determined.
which appeared concentration- and time-dependent. Furthermore, this activity persisted until 60 min of contact time.

Several items should be yet taken into consideration when analyzing these results. First, the different molecules were tested alone, i.e. without any additive as alcohol and without any interfering substances. In this way, their own anti-coronavirus activity could be estimated, but this was not really representative of field conditions, since viruses are normally found embedded in organic materials, preventing them from the action of ATS-D. These results are consistent with previous studies, which showed that CHX did not have ATS-D antiviral activity unless it was associated with cetrimide and 70% (v/v) ethanol (Sattar et al., 1989).

It would be of interest to associate the fast and persistent action of C[4]S-BTZ with that of alcoholic solutions. Indeed, even if ethanol showed a good ATS-D activity, in particular against coronaviruses (Rabenau et al., 2005b; Sattar et al., 1989), its volatile nature involves a transient action, which could potentially be improved by C[4]S-BTZ activities.

Furthermore, the absence of cytotoxicity made the C[4]S-BTZ even more promising, considering toxicity risks involved with the currently used ATS-D (skin reactions, allergy or occupational diseases).

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

Financial support was provided by the French Ministry of further Education and Research and French National Scientific Research Center.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.antiviral.2010.09.009.

References

Agence Française de normalisation (AFNOR), 2007. Chemical Disinfectants and Antiseptics—Virucidal Quantitative Suspension Test for Chemical Disinfectants and Antiseptics used in Human Medicine—Test Method and Requirements (phase 2, step 1), NF EN 14476 + A1.

American Society for Testing and Material (ASTM), 1996. Standard Test Method for Efficacy of Antimicrobial Agents against Viruses in Suspension, E1052-96 (last reapproval in 2002).

American Society for Testing and Material (ASTM), 1997. Standard Test Method for Efficacy of Virucidal Agents Intended for Inanimate Environmental Surfaces, E1053-97 (last reapproval in 2002).

Coveney, D., Costello, B., 2005. Preparation of alkylated pyrogallol calixarene type compounds as anti-viral compounds. U.S. Patent 113,454, (2005).

de Fátima, A., Fernandes, S.A., Sabino, A.A., 2009. Calixarenes as new platforms for drug design. Curr. Drug Discov. Technol. 6, 151–170.

Falsey, A.R., Walsh, E.E., Hayden, F.G., 2002. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J. Infect. Dis. 185, 1338–1341.

Gagneur, A., Sizun, J., Vallet, S., Legr, M.C., Picard, B., Talbot, P.J., 2002. Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study. J. Hosp. Infect. 51, 59–64.
Geller, C., Fontanay, S., Finance, C., Duval, R.E., 2009. A new Sephadex-based method for removing microbicidal and cytotoxic residues when testing antiseptics against viruses: experiments with a human coronavirus as a model. J. Virol. Methods 159, 217–226.

Gerna, G., Campannini, G., Rovida, F., Percivalle, E., Sarasini, A., Marchi, A., Baldanti, F., 2000. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J. Med. Virol. 78, 938–949.

Gerna, G., Percivalle, E., Sarasini, A., Campanini, G., Piralla, A., Rovida, F., Genini, E., Marchi, A., Baldanti, F., 2007. Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients. J. Clin. Virol. 38, 244–250.

Harris, S.J., 1995. Calixarene-based compounds having antibacterial, antifungal, anticancer-HIV activity. WO 95/19974.

Harris, S.J., 2002. Preparation of Calixarenes as anti-viral compounds. WO 02/44121.

Hwang, K.M., Qi, Y.M., Liu, S.Y., Choy, W., 1994. Inhibition and treatment of infection by enveloped virus with calix[n]arene compounds. WO 94/03164.

Ijaz, M.K., Brunner, A.H., Sattar, S.A., Nair, R.C., Johnson-Lussenburg, C.M., 1985. Survival characteristics of airborne human coronavirus 229E. J. Gen. Virol. 66, 2743–2748.

Kral, V., Cigler, P., Konvalinka, J., Kozisek, M., Prejdova, J., Gruener, B., Plesek, J., Lepsik, M., Pokorna, J., Kraeusslich, H.-G., Bodem, J., 2005. Preparation and HIV protease inhibitory activity of novel mono- and dinuclear cobalt dicarboxilides. WO 2005073240.

Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J.A., Lim, W., Rollin, P.E., Dowell, S.F., Ling, A.E., Humphrey, C.D., Shieh, W.J., Guan, J., Paddock, C.D., Rota, P., Fields, B., DeRisi, J., Yang, J.V., Cox, N., Hughes, J.M., LeDuc, J.W., Bellini, W.J., Anderson, L.J., 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953–1966.

Lai, M.Y., Cheng, P.K., Lim, W.W., 2005. Survival of severe acute respiratory syndrome coronavirus. Clin. Infect. Dis. 41, e67–71.

Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J.H., Wang, H., Cramer, G., Hu, Z., Zhang, H., Zheng, J., McEachern, J., Field, H., Dazak, P., Eaton, B.T., Zhang, S., Wang, L.F., 2005. Bats are natural reservoirs of SARS-like coronavirus. Science 310, 676–679.

Motornaya, A.E., Alimbarova, L.M., Shokova, E.A., Kovalev, V.V., 2006. Synthesis and antitherpetic activity of N-(3-amino-1-adamantyl)calix[4]arenes. Pharm. Chem. J. 40, 68–72.

Mourer, M., Psychogios, N., Laumond, G., Aubertin, A.M., Regnouf-de-Vains, J.R., 2010. Synthesis and anti-HIV evaluation of water-soluble calixarene-based bithiazolyl podands. Bioorg. Med. Chem. 18, 36–45.

Peiris, J.S., Lai, S.T., Foon, L.L., Guan, Y., Yam, L.Y., Lim, W., Nicholls, J., Yee, W.K., Yan, W.W., Cheung, M.T., Cheng, V.C., Chan, K.H., Tsang, D.N., Yung, R.W., Ng, T.K., Yuen, K.Y., 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319–1325.

Pene, F., Melet, A., Vabret, A., Rozenberg, F., Buzyn, A., Dreyfus, F., Cario, A., Freymuth, F., Lebon, P., 2003. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin. Infect. Dis. 37, 929–932.

Rabenau, H.F., Cintal, J., Morgenstern, B., Bauer, G., Preiser, W., Doerr, H.W., 2005a. Stability and inactivation of SARS coronavirus. Med. Microbiol. Immunol. 194, 1–6.

Rabenau, H.F., Kampf, G., Cintal, J., Doerr, H.W., 2005b. Efficacy of various disinfectants against SARS Coronavirus. J. Hosp. Infect. 61, 107–111.

Rodik, R.V., Boyko, V.I., Kalchenko, V.I., 2009. Calixarenes in bio-medical researches. Curr. Med. Chem. 16, 1630–1655.

Sattar, S.A., Springthorpe, V.S., Karim, Y., Loro, P., 1989. Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses. Epidemiol. Infect. 102, 485–505.

Sizun, J., Yu, M.W., Talbot, P.J., 2000. Survival of human coronaviruses 229E and OC43 in suspension and after drying on surfaces: a possible source of hospital-acquired infections. J. Hosp. Infect. 46, 55–60.

Vijgen, L., Keyaerts, E., Moes, E., Thoelen, L, Wolants, E, Lemey, P, Vandamme, A.-M., Van Ranst, M., 2005. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J. Virol. 79, 1595–1604.